Mineralys Therapeutics, Inc. MLYS Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s additional paid-in capital?
- Mineralys Therapeutics, Inc. (MLYS) reported additional paid-in capital of $1.13B in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Mineralys Therapeutics, Inc.'s additional paid-in capital increased by 65.3% year-over-year, from $686.28M to $1.13B.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s additional paid-in capital?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s additional paid-in capital has grown at a 1169.1% compound annual growth rate (CAGR), from $540K to $1.1B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.